Knuff & Co LLC Purchases 50 Shares of Eli Lilly and Company (NYSE:LLY)

Knuff & Co LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 7.0% in the fourth quarter, HoldingsChannel reports. The fund owned 767 shares of the company’s stock after acquiring an additional 50 shares during the period. Knuff & Co LLC’s holdings in Eli Lilly and Company were worth $447,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $27,000. Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $35,000. Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $36,000. Finally, Family CFO Inc acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $40,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 2.8 %

Shares of Eli Lilly and Company stock traded down $20.94 during trading on Friday, hitting $734.97. The company’s stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78. The stock has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a price-to-earnings-growth ratio of 1.46 and a beta of 0.37. The stock has a 50-day moving average price of $761.06 and a two-hundred day moving average price of $671.38.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the previous year, the firm posted $1.62 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 26.0% on a year-over-year basis. Equities research analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. Barclays lifted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research report on Wednesday. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.